The FDA accepts for review AVEO Oncology’s (AVEO -2.9%) marketing application seeking approval of tivozanib for relapsed/refractory renal cell carcinoma.
The agency’s action date is March 31, 2021. No advisory committee meeting is planned.
https://seekingalpha.com/news/3579211-fda-accepts-aveo-application-for-tivozanib-for-kidney-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.